Is Ropremilast/Romigrastim included in medical insurance?

Romiplostim/Romiplostim is a protein drug that can be injected subcutaneously and belongs to the thrombopoietin receptor agonist (TPO-RA) class. It is primarily used in adult patients with chronicimmune thrombocytopenia (ITP) who have responded poorly to traditional treatments such as glucocorticoids, immunoglobulins, or splenectomy. Through once-weekly subcutaneous injection, Roprostim can specifically stimulate bone marrow megakaryocytes to produce platelets, thereby effectively reducing the risk of bleeding and improving patients' quality of life.

In clinical practice, doctors will flexibly adjust the dose according to the patient's platelet level, with the goal of maintaining platelets in a safe range that can reduce the risk of bleeding without significantly increasing the risk of thrombosis. For patients who require long-term maintenance treatment, Roprostim has good controllability and can be administered individually according to changes in blood images. In addition toITP, Roprostim is currently also exploring the treatment of chemotherapy-related thrombocytopenia and insufficient platelet production caused by bone marrow diseases, showing certain potential.

In terms of medical insurance coverage, roplastin has been included in the scope of medical insurance reimbursement in many countries and regions, significantly reducing the economic burden of long-term treatment. Some regions in the country have included it in the medical insurance negotiation catalog. After reimbursement, the patient's out-of-pocket payment ratio has been significantly reduced. In particular, patients with chronic ITP who require long-term medication can receive treatment earlier and more continuously without interrupting the course of treatment due to high drug prices. The inclusion of medical insurance not only improves patients' medication accessibility, but also improves treatment compliance, allowing more patients to receive effective intervention before their condition worsens.

However, the specific medical insurance reimbursement ratio and scope of application will vary due to differences in regional policies. Some areas may only cover specific indications. Patients should confirm policy details with the local medical insurance department or hospital before taking medicine.

Reference materials:https://en.wikipedia.org/wiki/Romiplostim